In this interview, Michael Schwenkert (Bio-Rad Laboratories; CA, USA) describes the challenges for development of CAR-T cell therapies that can be addressed using anti-idiotypic antibodies. He discusses how Bio-Rad generates custom antibodies for this purpose and for bioanalytical PK and immunogenicity assays.
If you enjoyed this interview, you might also like…
Immunogenicity of therapeutic protein products: current considerations for anti-drug antibody assay in Japan
Drug-target complex specific antibodies: an interview with Michael Schwenkert (Bio-Rad)
The challenges of assessing immunogenicity: an interview with Joao Pedras-Vasconcelos